Onward Therapeutics closes NT$900M (US$28M) Series B financing to advance oncology pipeline. The round includes new investors and supports clinical programs in Taiwan.
Amount Raised
$28 Million
Round Type
Series B
Investors
Description
Onward Therapeutics announced the closing of its Series B financing round totaling NT$900 million (approximately US$28 million), raised in two closings with the second in October 2026. This marks the company's first capital increase in Taiwan since relocating its global headquarters from Switzerland in October 2025. Existing shareholders including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International continued their support, while new institutional investors such as Beiley Biofund, Everbright Biofund, and others joined the round. The proceeds will fund clinical programs, manufacturing of clinical supplies, and early-stage R&D.
Quick answer
Onward Therapeutics SA raised $28 Million in a Series B round, dated November 17, 2026. Investors: Top Taiwan Venture Capital, MitoBitTech Venture, Hercules Bioventure Partners, Grand Fortune Venture Capital, Test Rite International Co., Ltd., Everbright Biofund, Beiley Biofund and Hong Kong Chlitina International. Onward Therapeutics SA is based in Vaud, Switzerland.
- How much did Onward Therapeutics SA raise?
- Onward Therapeutics SA raised $28 Million in a Series B round on November 17, 2026.
- Who invested in Onward Therapeutics SA?
- Top Taiwan Venture Capital, MitoBitTech Venture, Hercules Bioventure Partners, Grand Fortune Venture Capital, Test Rite International Co., Ltd., Everbright Biofund, Beiley Biofund and Hong Kong Chlitina International are named as investors in this round.
- What does Onward Therapeutics SA do?
- Onward Therapeutics SA is a clinical stage oncology company focused on developing innovative therapies for cancer treatment.
- Where is Onward Therapeutics SA based and how big is it?
- Onward Therapeutics SA is based in Vaud, Switzerland. Fundz records about 10 employees.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Onward Therapeutics SA that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- StimCardio raised $30M (Series A) on October 29, 2026.
- Tivic raised $85M (Series B) on October 27, 2026.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Rouge Therapeutics raised $58M (Series A) on October 6, 2026.
Who to call at Onward Therapeutics SA, and when
A new round usually means Onward Therapeutics SA is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Onward Therapeutics SA raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Onward Therapeutics SA, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Onward Therapeutics SA. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Onward Therapeutics SA raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansOnward Therapeutics SA raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.